+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pharmacovigilance and Drug Safety Software - Global Market Trajectory & Analytics

  • ID: 5140073
  • Report
  • April 2021
  • Region: Global
  • 181 pages
  • Global Industry Analysts, Inc
Global Pharmacovigilance and Drug Safety Software Market to Reach $201.8 Million by 2027

Amid the COVID-19 crisis, the global market for Pharmacovigilance and Drug Safety Software estimated at US$143 Million in the year 2020, is projected to reach a revised size of US$201.8 Million by 2027, growing at a CAGR of 5.1% over the analysis period 2020-2027. ADR Reporting, one of the segments analyzed in the report, is projected to record a 4.5% CAGR and reach US$92 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Drug Safety Audits segment is readjusted to a revised 4.9% CAGR for the next 7-year period.



The U.S. Market is Estimated at $42.1 Million, While China is Forecast to Grow at 4.8% CAGR

The Pharmacovigilance and Drug Safety Software market in the U.S. is estimated at US$42.1 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$35.7 Million by the year 2027 trailing a CAGR of 4.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.9% and 4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Issue Tracking Segment to Record 5.4% CAGR

In the global Issue Tracking segment, USA, Canada, Japan, China and Europe will drive the 5.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$19.8 Million in the year 2020 will reach a projected size of US$28.6 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$23.3 Million by the year 2027.

Select Competitors (Total 47 Featured):
  • AB Cube
  • ArisGlobal LLC
  • Ennov USA
  • Extedo GmbH
  • Online Business Applications, Inc.
  • Oracle Corporation
  • Sarjen Systems Pvt. Ltd.
  • Sparta Systems, Inc.
  • United Biosource Corporation
Note: Product cover images may vary from those shown
I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Current & Future Analysis for Pharmacovigilance and Drug Safety Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
  • Table 2: World 7-Year Perspective for Pharmacovigilance and Drug Safety Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
  • Table 3: World Current & Future Analysis for ADR Reporting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
  • Table 4: World 7-Year Perspective for ADR Reporting by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 5: World Current & Future Analysis for Drug Safety Audits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
  • Table 6: World 7-Year Perspective for Drug Safety Audits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 7: World Current & Future Analysis for Issue Tracking by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
  • Table 8: World 7-Year Perspective for Issue Tracking by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 9: World Current & Future Analysis for Fully Integrated Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
  • Table 10: World 7-Year Perspective for Fully Integrated Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 11: World Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
  • Table 12: World 7-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 13: World Current & Future Analysis for CROs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
  • Table 14: World 7-Year Perspective for CROs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 15: World Current & Future Analysis for BPOs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
  • Table 16: World 7-Year Perspective for BPOs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 17: World Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
  • Table 18: World 7-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 19: World Current & Future Analysis for On-premise by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
  • Table 20: World 7-Year Perspective for On-premise by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 21: World Current & Future Analysis for On-demand by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
  • Table 22: World 7-Year Perspective for On-demand by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
III. MARKET ANALYSIS
  • UNITED STATES
  • Table 23: USA Current & Future Analysis for Pharmacovigilance and Drug Safety Software by Functionality - ADR Reporting, Drug Safety Audits, Issue Tracking and Fully Integrated Software - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 24: USA 7-Year Perspective for Pharmacovigilance and Drug Safety Software by Functionality - Percentage Breakdown of Value Sales for ADR Reporting, Drug Safety Audits, Issue Tracking and Fully Integrated Software for the Years 2020 & 2027
  • Table 25: USA Current & Future Analysis for Pharmacovigilance and Drug Safety Software by End-Use - Pharma & Biotech Companies, CROs, BPOs and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 26: USA 7-Year Perspective for Pharmacovigilance and Drug Safety Software by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs, BPOs and Other End-Uses for the Years 2020 & 2027
  • Table 27: USA Current & Future Analysis for Pharmacovigilance and Drug Safety Software by Deployment Model - On-premise and On-demand - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 28: USA 7-Year Perspective for Pharmacovigilance and Drug Safety Software by Deployment Model - Percentage Breakdown of Value Sales for On-premise and On-demand for the Years 2020 & 2027
  • CANADA
  • Table 29: Canada Current & Future Analysis for Pharmacovigilance and Drug Safety Software by Functionality - ADR Reporting, Drug Safety Audits, Issue Tracking and Fully Integrated Software - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 30: Canada 7-Year Perspective for Pharmacovigilance and Drug Safety Software by Functionality - Percentage Breakdown of Value Sales for ADR Reporting, Drug Safety Audits, Issue Tracking and Fully Integrated Software for the Years 2020 & 2027
  • Table 31: Canada Current & Future Analysis for Pharmacovigilance and Drug Safety Software by End-Use - Pharma & Biotech Companies, CROs, BPOs and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 32: Canada 7-Year Perspective for Pharmacovigilance and Drug Safety Software by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs, BPOs and Other End-Uses for the Years 2020 & 2027
  • Table 33: Canada Current & Future Analysis for Pharmacovigilance and Drug Safety Software by Deployment Model - On-premise and On-demand - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 34: Canada 7-Year Perspective for Pharmacovigilance and Drug Safety Software by Deployment Model - Percentage Breakdown of Value Sales for On-premise and On-demand for the Years 2020 & 2027
  • JAPAN
  • Table 35: Japan Current & Future Analysis for Pharmacovigilance and Drug Safety Software by Functionality - ADR Reporting, Drug Safety Audits, Issue Tracking and Fully Integrated Software - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 36: Japan 7-Year Perspective for Pharmacovigilance and Drug Safety Software by Functionality - Percentage Breakdown of Value Sales for ADR Reporting, Drug Safety Audits, Issue Tracking and Fully Integrated Software for the Years 2020 & 2027
  • Table 37: Japan Current & Future Analysis for Pharmacovigilance and Drug Safety Software by End-Use - Pharma & Biotech Companies, CROs, BPOs and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 38: Japan 7-Year Perspective for Pharmacovigilance and Drug Safety Software by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs, BPOs and Other End-Uses for the Years 2020 & 2027
  • Table 39: Japan Current & Future Analysis for Pharmacovigilance and Drug Safety Software by Deployment Model - On-premise and On-demand - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 40: Japan 7-Year Perspective for Pharmacovigilance and Drug Safety Software by Deployment Model - Percentage Breakdown of Value Sales for On-premise and On-demand for the Years 2020 & 2027
  • CHINA
  • Table 41: China Current & Future Analysis for Pharmacovigilance and Drug Safety Software by Functionality - ADR Reporting, Drug Safety Audits, Issue Tracking and Fully Integrated Software - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 42: China 7-Year Perspective for Pharmacovigilance and Drug Safety Software by Functionality - Percentage Breakdown of Value Sales for ADR Reporting, Drug Safety Audits, Issue Tracking and Fully Integrated Software for the Years 2020 & 2027
  • Table 43: China Current & Future Analysis for Pharmacovigilance and Drug Safety Software by End-Use - Pharma & Biotech Companies, CROs, BPOs and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 44: China 7-Year Perspective for Pharmacovigilance and Drug Safety Software by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs, BPOs and Other End-Uses for the Years 2020 & 2027
  • Table 45: China Current & Future Analysis for Pharmacovigilance and Drug Safety Software by Deployment Model - On-premise and On-demand - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 46: China 7-Year Perspective for Pharmacovigilance and Drug Safety Software by Deployment Model - Percentage Breakdown of Value Sales for On-premise and On-demand for the Years 2020 & 2027
  • EUROPE
  • Table 47: Europe Current & Future Analysis for Pharmacovigilance and Drug Safety Software by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
  • Table 48: Europe 7-Year Perspective for Pharmacovigilance and Drug Safety Software by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
  • Table 49: Europe Current & Future Analysis for Pharmacovigilance and Drug Safety Software by Functionality - ADR Reporting, Drug Safety Audits, Issue Tracking and Fully Integrated Software - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 50: Europe 7-Year Perspective for Pharmacovigilance and Drug Safety Software by Functionality - Percentage Breakdown of Value Sales for ADR Reporting, Drug Safety Audits, Issue Tracking and Fully Integrated Software for the Years 2020 & 2027
  • Table 51: Europe Current & Future Analysis for Pharmacovigilance and Drug Safety Software by End-Use - Pharma & Biotech Companies, CROs, BPOs and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 52: Europe 7-Year Perspective for Pharmacovigilance and Drug Safety Software by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs, BPOs and Other End-Uses for the Years 2020 & 2027
  • Table 53: Europe Current & Future Analysis for Pharmacovigilance and Drug Safety Software by Deployment Model - On-premise and On-demand - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 54: Europe 7-Year Perspective for Pharmacovigilance and Drug Safety Software by Deployment Model - Percentage Breakdown of Value Sales for On-premise and On-demand for the Years 2020 & 2027
  • FRANCE
  • Table 55: France Current & Future Analysis for Pharmacovigilance and Drug Safety Software by Functionality - ADR Reporting, Drug Safety Audits, Issue Tracking and Fully Integrated Software - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 56: France 7-Year Perspective for Pharmacovigilance and Drug Safety Software by Functionality - Percentage Breakdown of Value Sales for ADR Reporting, Drug Safety Audits, Issue Tracking and Fully Integrated Software for the Years 2020 & 2027
  • Table 57: France Current & Future Analysis for Pharmacovigilance and Drug Safety Software by End-Use - Pharma & Biotech Companies, CROs, BPOs and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 58: France 7-Year Perspective for Pharmacovigilance and Drug Safety Software by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs, BPOs and Other End-Uses for the Years 2020 & 2027
  • Table 59: France Current & Future Analysis for Pharmacovigilance and Drug Safety Software by Deployment Model - On-premise and On-demand - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 60: France 7-Year Perspective for Pharmacovigilance and Drug Safety Software by Deployment Model - Percentage Breakdown of Value Sales for On-premise and On-demand for the Years 2020 & 2027
  • GERMANY
  • Table 61: Germany Current & Future Analysis for Pharmacovigilance and Drug Safety Software by Functionality - ADR Reporting, Drug Safety Audits, Issue Tracking and Fully Integrated Software - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 62: Germany 7-Year Perspective for Pharmacovigilance and Drug Safety Software by Functionality - Percentage Breakdown of Value Sales for ADR Reporting, Drug Safety Audits, Issue Tracking and Fully Integrated Software for the Years 2020 & 2027
  • Table 63: Germany Current & Future Analysis for Pharmacovigilance and Drug Safety Software by End-Use - Pharma & Biotech Companies, CROs, BPOs and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 64: Germany 7-Year Perspective for Pharmacovigilance and Drug Safety Software by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs, BPOs and Other End-Uses for the Years 2020 & 2027
  • Table 65: Germany Current & Future Analysis for Pharmacovigilance and Drug Safety Software by Deployment Model - On-premise and On-demand - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 66: Germany 7-Year Perspective for Pharmacovigilance and Drug Safety Software by Deployment Model - Percentage Breakdown of Value Sales for On-premise and On-demand for the Years 2020 & 2027
  • ITALY
  • Table 67: Italy Current & Future Analysis for Pharmacovigilance and Drug Safety Software by Functionality - ADR Reporting, Drug Safety Audits, Issue Tracking and Fully Integrated Software - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 68: Italy 7-Year Perspective for Pharmacovigilance and Drug Safety Software by Functionality - Percentage Breakdown of Value Sales for ADR Reporting, Drug Safety Audits, Issue Tracking and Fully Integrated Software for the Years 2020 & 2027
  • Table 69: Italy Current & Future Analysis for Pharmacovigilance and Drug Safety Software by End-Use - Pharma & Biotech Companies, CROs, BPOs and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 70: Italy 7-Year Perspective for Pharmacovigilance and Drug Safety Software by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs, BPOs and Other End-Uses for the Years 2020 & 2027
  • Table 71: Italy Current & Future Analysis for Pharmacovigilance and Drug Safety Software by Deployment Model - On-premise and On-demand - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 72: Italy 7-Year Perspective for Pharmacovigilance and Drug Safety Software by Deployment Model - Percentage Breakdown of Value Sales for On-premise and On-demand for the Years 2020 & 2027
  • UNITED KINGDOM
  • Table 73: UK Current & Future Analysis for Pharmacovigilance and Drug Safety Software by Functionality - ADR Reporting, Drug Safety Audits, Issue Tracking and Fully Integrated Software - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 74: UK 7-Year Perspective for Pharmacovigilance and Drug Safety Software by Functionality - Percentage Breakdown of Value Sales for ADR Reporting, Drug Safety Audits, Issue Tracking and Fully Integrated Software for the Years 2020 & 2027
  • Table 75: UK Current & Future Analysis for Pharmacovigilance and Drug Safety Software by End-Use - Pharma & Biotech Companies, CROs, BPOs and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 76: UK 7-Year Perspective for Pharmacovigilance and Drug Safety Software by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs, BPOs and Other End-Uses for the Years 2020 & 2027
  • Table 77: UK Current & Future Analysis for Pharmacovigilance and Drug Safety Software by Deployment Model - On-premise and On-demand - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 78: UK 7-Year Perspective for Pharmacovigilance and Drug Safety Software by Deployment Model - Percentage Breakdown of Value Sales for On-premise and On-demand for the Years 2020 & 2027
  • REST OF EUROPE
  • Table 79: Rest of Europe Current & Future Analysis for Pharmacovigilance and Drug Safety Software by Functionality - ADR Reporting, Drug Safety Audits, Issue Tracking and Fully Integrated Software - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 80: Rest of Europe 7-Year Perspective for Pharmacovigilance and Drug Safety Software by Functionality - Percentage Breakdown of Value Sales for ADR Reporting, Drug Safety Audits, Issue Tracking and Fully Integrated Software for the Years 2020 & 2027
  • Table 81: Rest of Europe Current & Future Analysis for Pharmacovigilance and Drug Safety Software by End-Use - Pharma & Biotech Companies, CROs, BPOs and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 82: Rest of Europe 7-Year Perspective for Pharmacovigilance and Drug Safety Software by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs, BPOs and Other End-Uses for the Years 2020 & 2027
  • Table 83: Rest of Europe Current & Future Analysis for Pharmacovigilance and Drug Safety Software by Deployment Model - On-premise and On-demand - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 84: Rest of Europe 7-Year Perspective for Pharmacovigilance and Drug Safety Software by Deployment Model - Percentage Breakdown of Value Sales for On-premise and On-demand for the Years 2020 & 2027
  • ASIA-PACIFIC
  • Table 85: Asia-Pacific Current & Future Analysis for Pharmacovigilance and Drug Safety Software by Functionality - ADR Reporting, Drug Safety Audits, Issue Tracking and Fully Integrated Software - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 86: Asia-Pacific 7-Year Perspective for Pharmacovigilance and Drug Safety Software by Functionality - Percentage Breakdown of Value Sales for ADR Reporting, Drug Safety Audits, Issue Tracking and Fully Integrated Software for the Years 2020 & 2027
  • Table 87: Asia-Pacific Current & Future Analysis for Pharmacovigilance and Drug Safety Software by End-Use - Pharma & Biotech Companies, CROs, BPOs and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 88: Asia-Pacific 7-Year Perspective for Pharmacovigilance and Drug Safety Software by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs, BPOs and Other End-Uses for the Years 2020 & 2027
  • Table 89: Asia-Pacific Current & Future Analysis for Pharmacovigilance and Drug Safety Software by Deployment Model - On-premise and On-demand - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 90: Asia-Pacific 7-Year Perspective for Pharmacovigilance and Drug Safety Software by Deployment Model - Percentage Breakdown of Value Sales for On-premise and On-demand for the Years 2020 & 2027
  • REST OF WORLD
  • Table 91: Rest of World Current & Future Analysis for Pharmacovigilance and Drug Safety Software by Functionality - ADR Reporting, Drug Safety Audits, Issue Tracking and Fully Integrated Software - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 92: Rest of World 7-Year Perspective for Pharmacovigilance and Drug Safety Software by Functionality - Percentage Breakdown of Value Sales for ADR Reporting, Drug Safety Audits, Issue Tracking and Fully Integrated Software for the Years 2020 & 2027
  • Table 93: Rest of World Current & Future Analysis for Pharmacovigilance and Drug Safety Software by End-Use - Pharma & Biotech Companies, CROs, BPOs and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 94: Rest of World 7-Year Perspective for Pharmacovigilance and Drug Safety Software by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs, BPOs and Other End-Uses for the Years 2020 & 2027
  • Table 95: Rest of World Current & Future Analysis for Pharmacovigilance and Drug Safety Software by Deployment Model - On-premise and On-demand - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 96: Rest of World 7-Year Perspective for Pharmacovigilance and Drug Safety Software by Deployment Model - Percentage Breakdown of Value Sales for On-premise and On-demand for the Years 2020 & 2027
IV. COMPETITION
  • Total Companies Profiled: 47
Note: Product cover images may vary from those shown
Adroll
adroll